Leena Gandhi | Director, Center for Therapeutic Innovation
Dana Farber Cancer Institute

Leena Gandhi, Director, Center for Therapeutic Innovation, Dana Farber Cancer Institute

Dr. Leena Gandhi currently serves as Vice President, Immuno-Oncology Development at Eli Lilly.  She previously was an associate professor of medicine at NYU Perlmutter Cancer Center where she served as Director of Thoracic Medical Oncology from 2016-2018 and prior to that she worked as a thoracic oncologist in the Early Drug Development Center at Dana-Farber Cancer Institute.  Her focus of research has been on novel therapeutics in lung cancer with a focus on immuno-oncology and biomarkers of immunotherapy response in lung cancer as well as modulation of the immune microenvironment by chemotherapies and other therapies.  She was a lead investigator in defining PD-L1 biomarkers used for pembrolizumab therapy in NSCLC.

Appearances:



Day 3, September 30th @ 16:20

Panel: Targeted approaches to combinations, what’s working?

  • What strategies can we use to identify the best combinations?
    • Using immunology as a guide?
    • Combinations of any active compound?
  • What are the major mechanisms we need to focus on?
  • How successful have targeted combinations been so far?
    • IO-IO/ IO-Non-IO combos / Targeting the TME / Angiogenesis inhibitors / Standard of care agents
  • What are the best biomarkers for combination studies?
  • What major challenges remain?
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT

back to speakers